Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Schwarz, Diana [BioRegio STERN]. (9/18/14). "News: Interview mit Dr. Ingmar Hoerr zur Kooperation von CureVac und Boehringer Ingelheim".

Region Region Germany
Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 CureVac GmbH
  Today CureVac AG
Products Product CV9202 mRNA cancer vaccine
  Product 2 afatinib
Index term Index term Boehringer–CureVac: RNActive vaccine, 20140901– collab developm + excl ww license for CV9202 €35m upfront + €430m milestones + royalties
Person Person Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
     


   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top